(May 4, 2020, 1:56 PM EDT) -- WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals on May 1 said the Food and Drug Administration’s denial of an application for an abuse-deterrent formulation (ADF) for opioids was “reasonable and consistent with law” and that the agency’s denial of a hearing on the denial was not an abuse of discretion (Pharmaceutical Manufacturing Research Services, Inc. v. Food & Drug Administration, et al., No. 18-1335, D.C. Cir., 2020 U.S. App. LEXIS 14043)....